Sugi Predict

Sugi Predict / Targets / PSMD4

PSMD4

26S proteasome non-ATPase regulatory subunit · P55036 · PSMD4 on Sugi Atlas →

7,695 patent compounds predicted against PSMD4, 6,081 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1478606 SCHEMBL1478606 0.58 12/20
SCHEMBL607010 SCHEMBL607010 0.56 12/20
SCHEMBL608381 SCHEMBL608381 0.53 12/20
SCHEMBL606616 SCHEMBL606616 0.51 12/20
SCHEMBL1477637 SCHEMBL1477637 0.57 11/20
SCHEMBL607972 SCHEMBL607972 0.55 11/20
SCHEMBL608782 SCHEMBL608782 0.54 11/20
SCHEMBL609278 SCHEMBL609278 0.54 11/20
SCHEMBL607553 SCHEMBL607553 0.54 11/20
SCHEMBL605822 SCHEMBL605822 0.54 11/20
SCHEMBL606932 SCHEMBL606932 0.53 11/20
SCHEMBL1477893 SCHEMBL1477893 0.53 11/20
SCHEMBL608362 SCHEMBL608362 0.53 11/20
SCHEMBL608599 SCHEMBL608599 0.53 11/20
SCHEMBL1327441 SCHEMBL1327441 0.53 11/20
SCHEMBL605129 SCHEMBL605129 0.52 11/20
SCHEMBL608009 SCHEMBL608009 0.52 11/20
SCHEMBL1478157 SCHEMBL1478157 0.52 11/20
SCHEMBL609081 SCHEMBL609081 0.52 11/20
SCHEMBL606926 SCHEMBL606926 0.52 11/20

Clinical trials — most relevant to PSMD4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease PHASE4UNKNOWN
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
Biologic Correlative Taxotere/AC PHASE2COMPLETED
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
A Prevention Trial in Subjects at High Risk for Breast Cancer PHASE2COMPLETED
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors PHASE2COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM PHASE1WITHDRAWN
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma PHASE1COMPLETED
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment nanUNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS) nanUNKNOWN
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Quantification of GADD34 Expression in RA nanCOMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit nanCOMPLETED
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT) nanUNKNOWN
Collection of Blood Samples for DNA in Motor Neuron Disease nanCOMPLETED
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve nanUNKNOWN
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure nanCOMPLETED
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq) nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a PSMD4 binder may also engage these)

ProteinNameSimilarity
O35226 — 1.000 O35226 →
Q58DA0 — 0.999 Q58DA0 →
P55035 — 0.994 P55035 →
O17453 — 0.979 O17453 →
P55034 — 0.975 P55034 →
O61742 — 0.974 O61742 →
O82143 — 0.974 O82143 →
Q8K339 — 0.967 Q8K339 →
Q84L32 — 0.966 Q84L32 →
P70483 — 0.966 P70483 →
Q7X923 — 0.966 Q7X923 →
P54729 — 0.965 P54729 →
Q9VUV9 — 0.965 Q9VUV9 →
Q9NYL9 — 0.965 Q9NYL9 →
Q2USD7 — 0.965 Q2USD7 →
Q9UNN5 — 0.965 Q9UNN5 →
Q84L33 — 0.965 Q84L33 →
Q9QXU8 — 0.965 Q9QXU8 →
O00151 — 0.965 O00151 →
Q1EBV4 — 0.964 Q1EBV4 →
Q98SH3 — 0.964 Q98SH3 →
Q6P2K6 — 0.964 Q6P2K6 →
PPP4R3A Serine/threonine-protein phosphatase 4 regulatory subunit 3A 0.964 landscape →
Q62760 — 0.964 Q62760 →
Q8H6B1 — 0.963 Q8H6B1 →
B4F7E7 — 0.963 B4F7E7 →
Q8LCV1 — 0.963 Q8LCV1 →
Q9NZR1 — 0.963 Q9NZR1 →
Q9JHJ0 — 0.963 Q9JHJ0 →
Q5XI81 — 0.963 Q5XI81 →